【摘要】 目的比较糖耐量受损(IGT)人群药物干预与非药物干预对糖尿病发病率的作用,观察吡格列酮对糖耐量受损IGT干预治疗的疗效。方法200例住院或门诊经口服75克葡萄糖耐量试验OGTT筛查证实为IGT的病人,分成对照组、饮食加运动组、阿卡波糖组、二甲双胍组和吡格列酮组,进行1年干预治疗研究。结果初访时5组基线资料无统计学差异,1年后,对照组空腹血糖FPG无变化,OGTT后2小时血糖2hPG轻度升高,每年糖尿病发病率为12.0%;饮食加运动组FPG及2hPG轻度下降,每年糖尿病的发病率为10.0%,阿卡波糖组、二甲双胍组和吡格列酮组FPG及2hPG均有显著下降,每年糖尿病发病率分别为4.3%、2.2%和2.0%。药物组1年末平均FPG与对照组、饮食加运动组比较差异有显著性。吡格列酮组改善胰岛素敏感指数与其余4组相比差异有显著性意义。结论在IGT干预治疗中,药物干预治疗可达到显著地减少糖尿病发生的效果。吡格列酮在IGT干预治疗中剂量小,胰岛素敏感性增强优于其他药物。更多还原

【Abstract】 Objective To observe the effect of drug intervention and non-drug intervention on diabetes mellitus(DM) morbidity in patients with impaired glucose tolerance(IGT). To evaluate the intervention effect of Pioglitazone on the IGT population from becoming diabetes mellitus: Methods 200 patients with IGT diagnosed by orally glucose tolerance test (OGTT) were randomly divided into 5 groups: received therapy with placebo (control group), alimentary control & exercise, Acarbose, Metformin or Pioglitazone respectively. The data were assayed after 1-year intervention treatment. Results The baseline data wasn’t significant diversity befor treatment, after one year there was no changer in fasting plasma glucose (FPG), slight increase in 2h-plasma glucose after OGTT and 12% DM morbidity in control group; light decrease in both FPG and 2h-PG, 10% DM morbidity in alimentary control & exercise group; while overt decrease in both FPG and 2h-PG in Acrbose, Metformin or Pioglitazone group(P<0.05), and 4.3%, 2.2%,2.0%DM morbidity respectively. There was significant decrease in average FPG in drug group, increase in insulin sensitivity index (ISI) in Pioglitazone group, compared with other group on 1 year-end(P<0.05). Conclusion DM morbidity is significant decreased by drug intervention in patients with IGT, Pioglitazone is superior to other durg in improve insulin sensitivity due to low dose更多还原